Validated green ultra-fast UPLC-MS/MS method for the quantification of fedratinib in an HLM matrix: application to in vitro and in silico metabolic stability studies

Abstract

Fedratinib (INREBIC®; FDB), an orally administered selective Janus kinase 2 (JAK-2) inhibitor, has been approved by the FDA for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis in adult patients. This study established a sensitive, fast, green, and dependable UPLC-MS/MS approach for quantifying FDB in human liver microsomes (HLMs); moreover, this approach was employed to assess the in vitro metabolic stability of FDB in HLMs. The validation steps of the UPLC-MS/MS approach adhered to the US-FDA principles for bioanalytical method validation. The StarDrop program, incorporating the DEREK and P450 modules, was employed to monitor the FDB chemical structure alerts and in silico metabolic lability, respectively. FDB and encorafenib (ENB as the IS) were analyzed using the isocratic mobile phase method on an Eclipse Plus C18 column. The developed UPLC-MS/MS method exhibited an ultra-fast (1 min), wide linearity range (1.0–3000 ng mL−1) with good separation of the target analytes and was accurate and reproducible in the absence of HLM matrix effects. The current study evaluated the precision and accuracy of the UPLC-MS/MS method for intra-day and inter-day assessments, varying from −5.33% to 5.56% and −9.00% to 6.67%, respectively. The intrinsic clearance (Clint) of FDB was measured at 34.86 mL min−1 kg−1, whereas the in vitro half-life (t1/2) was determined to be 23.26 min. In silico screening indicated that minor structural modifications to the pyrrolidine moiety in the process of drug design could increase metabolic stability and enhance safety relative to FDB. The assessment of in silico FDB ADME properties and metabolic stability is important for the progression of novel drug discovery aimed at improving metabolic stability.

Graphical abstract: Validated green ultra-fast UPLC-MS/MS method for the quantification of fedratinib in an HLM matrix: application to in vitro and in silico metabolic stability studies

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Paper
Submitted
27 Mar 2025
Accepted
16 Jun 2025
First published
01 Jul 2025

Anal. Methods, 2025, Advance Article

Validated green ultra-fast UPLC-MS/MS method for the quantification of fedratinib in an HLM matrix: application to in vitro and in silico metabolic stability studies

M. W. Attwa, A. S. Abdelhameed and A. A. Kadi, Anal. Methods, 2025, Advance Article , DOI: 10.1039/D5AY00513B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements